<DOC>
	<DOCNO>NCT00153998</DOCNO>
	<brief_summary>General Objectives : - To test feasibility neoadjuvant treatment cetuximab/chemotherapy follow liver resection - To determine optimal combination ( cetuximab/FOLFOX versus cetuximab/FOLFIRI ) trial preoperative chemotherapy</brief_summary>
	<brief_title>Cetuximab Neoadjuvant Treatment Non-Resectable Colorectal Liver Metastases ( CELIM )</brief_title>
	<detailed_description>Patients liver metastasis screen study . Eligible patient complete pretreatment evaluation include abdominal CT scan present local surgeon radiologist prove resectability hepatic lesion . Additionally , CT scan review three reference surgeon . In case non-resectability , define , CT- ultrasound- guide biopsy one liver metastases perform , unless biopsy material available prior biopsy one liver metastases . Instead ultrasound-guided biopsy , CT-guided biopsy may perform . Formalin-fixed , paraffin embed metastatic tissue send reference laboratory ( Prof. Störkel , Wuppertal ) immunohistochemical analysis EGFR- expression . Additionally tissue store `` RNA later '' gene expression analysis agree patient . Additionally , primary tumor collect sent reference laboratory analysis EGFR- expression ( agreement patient exist ) . Patients randomized combination : Cetuximab/FOLFIRI ( irinotecan/5-FU/FA ) Cetuximab/FOLFOX6 ( oxaliplatin/5-FU/FA ) All patient receive four month treatment ( eight cycle ) allocate treatment . Resection plan completion neoadjuvant treatment perform 4 6 week last dose chemotherapy . Probes resect material ( liquid nitrogen paraffin embed material collect ) . If resection possible eight administration chemotherapy , chemotherapy continue tumor progression ( maximal duration treatment 2 year ) patient evaluate potential resection every two month . After resection , postoperative treatment plan 3 month ( 6 cycle ) . Treatment start plan 4 8 week operation .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Patients nonresectable , histologically confirm , synchronous metachronous colorectal liver metastasis . Patients nonresectable metastasis define ; patient five liver metastasis ; and/or patient liver metastasis technically nonresectable ( local surgeon cooperation local radiologist define nonresectability basis remain functional liver tissue , infiltration liver vein , infiltration liver artery , portal branch bile duct ) . Patients simultaneous liver metastasis eligible , primary tumor resect least 1 month prior chemotherapy . Karnofsky Performance Status ≥ 80 Informed consent Adequate bone marrow function , liver renal function ( neutrophils &gt; 1.5 x 10^9/l ; thrombocyte &gt; 100 x 10^9/l ; hemoglobin &gt; 8.0 g/l ; bilirubin ≤ 1.5 x upper limit normal [ ULN ] increase 25 % within last 4 week ; ALAT ASAT &lt; 5 x UNL ; serum creatinine ≤ 1.5 x UNL ) Age ≥ 18 year Any evidence extrahepatic metastasis , lymph node metastasis primary tumor recurrence Prior chemotherapy ( except adjuvant chemotherapy interval ≥ 6 month ) Previous exposure EGFR ( epidermal growth factor receptor ) target therapy Radiotherapy major abdominal thoracic surgery ( exclude diagnostic biopsy port implantation ) ≤ 4 week study entry Concurrent systemic immune therapy , chemotherapy , hormone therapy Investigational agent participation clinical trial within 30 day start treatment study Clinically relevant coronary disease myocardial infarction within 12 month study entry Peripheral neuropathy &gt; CTC grade I Inflammatory bowel disease Previous malignancy ( except colorectal cancer , history basal cell carcinoma skin preinvasive carcinoma cervix adequate treatment ) History severe psychiatric illness Drug alcohol abuse Breast feeding pregnant woman , effective contraception risk conception exists ( male female patient )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Cetuximab</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>5-FU</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Resection</keyword>
	<keyword>Liver resection</keyword>
	<keyword>Neoadjuvant</keyword>
</DOC>